FDA Clears DyAnsys Neurostimulation Device First Relief to treat Diabetic Neuropathic Pain
PALO ALTO, Calif., July 14, 2022 /PRNewswire/ — First Relief, a PENS (percutaneous electrical neurostimulation) device, has been cleared by the US Food and Drug Administration for multiple treatments up to 56 days for symptomatic relief of chronic, intractable pain from diabetic peripheral neuropathy, Dyansys Inc. has announced. The First Relief percutaneous neurostimulation device can […]
